Reality Check on Cystic Fibrosis
Market access for cystic fibrosis (CF) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: More than half of the covered lives under the pharmacy benefit in health exchange programs and Medicare formularies have some type of utilization management restriction
- Class Trends: Even with a host of medications to treat the condition, challenges to managing CF exist, including the high cost of care, drug burden and having to get multiple medicines from more than one pharmacy
- Key Findings: Contracting is prevalent amongst the antibiotics, which are available under various brand names. Competition will increase as more antibiotics enter the CF market
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.